The impact of signet-ring cell carcinoma histology on bladder cancer outcome
- PMID: 21706144
- DOI: 10.1007/s00345-011-0718-8
The impact of signet-ring cell carcinoma histology on bladder cancer outcome
Abstract
Background: Signet-ring cell carcinoma (SRCC) of the urinary bladder is a rare entity. No previous studies have directly compared the cancer-specific survival of patients with SRCC to patients with urothelial carcinoma (UC) of the urinary bladder.
Materials and methods: Patients with diagnosis of urinary bladder SRCC and UC were identified in the Surveillance, epidemiology, and end results program (SEER) (2001-2004). Demographic of patients and clinical characteristics at diagnosis were compared. Differences in cancer-specific survival were compared using univariate and multivariate analysis.
Results: A total of 103 patients with SRCC and 14,648 patients with UC were indentified. Patients with SRCC were younger (P < 0.001), more commonly presented with higher-grade histology (P < 0.001) and advanced stage disease (P < 0.001), in comparison with patients with UC. The 3-year cancer-specific survival rate was 67.0% for patients with UC and 33.2% for SRCC. On multivariate analysis, there was an increased mortality risk in patients with SRCC versus UC (HR 1.49, 95% CI 1.11-2.00, P < 0.01).
Conclusions: Even after adjusting for demographic, surgical, and pathological factors, cancer-specific survival rate was significantly worse in patients with SRCC compared to UC. Further research into the biology of this rare tumor is required to explain these results.
Similar articles
-
Treatment Options for Signet Ring Cell Carcinoma of the Urinary Bladder: A Population-Based Study.Cancer Control. 2024 Jan-Dec;31:10732748241278485. doi: 10.1177/10732748241278485. Cancer Control. 2024. PMID: 39159955 Free PMC article.
-
Molecular genetic and clinical characteristic analysis of primary signet ring cell carcinoma of urinary bladder identified by a novel OR2L5 mutation.Cancer Med. 2023 Feb;12(4):3931-3951. doi: 10.1002/cam4.5121. Epub 2022 Aug 11. Cancer Med. 2023. PMID: 36779496 Free PMC article.
-
Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA.Int J Urol. 2017 Feb;24(2):117-123. doi: 10.1111/iju.13261. Epub 2016 Nov 22. Int J Urol. 2017. PMID: 27875858
-
An updated review on primary signet-ring cell carcinoma of the urinary bladder and report of a case.Scand J Urol. 2018 Apr;52(2):87-93. doi: 10.1080/21681805.2017.1418020. Epub 2018 Jan 1. Scand J Urol. 2018. PMID: 29291665 Review.
-
A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy.J Urol. 2020 Dec;204(6):1129-1140. doi: 10.1097/JU.0000000000001305. Epub 2020 Jul 27. J Urol. 2020. PMID: 32716694
Cited by
-
Development and validation of a nomogram for predicting survival in patients with non-metastatic primary adenocarcinoma of the bladder.Transl Cancer Res. 2020 Sep;9(9):5155-5165. doi: 10.21037/tcr-20-354. Transl Cancer Res. 2020. PMID: 35117882 Free PMC article.
-
Primary signet-ring cell carcinoma of the urinary bladder.Autops Case Rep. 2021 Apr 22;11:e2021264. doi: 10.4322/acr.2021.264. Autops Case Rep. 2021. PMID: 33968831 Free PMC article.
-
Risk of Rare Cancers Among Solid Organ Transplant Recipients.J Natl Cancer Inst. 2021 Feb 1;113(2):199-207. doi: 10.1093/jnci/djaa078. J Natl Cancer Inst. 2021. PMID: 32462187 Free PMC article.
-
Signet-Ring Cell Carcinoma as an Independent Prognostic Factor for Patients With Urinary Bladder Cancer: A Population-Based Study.Front Oncol. 2020 May 15;10:653. doi: 10.3389/fonc.2020.00653. eCollection 2020. Front Oncol. 2020. PMID: 32500022 Free PMC article.
-
A model for predicting overall survival in bladder cancer patients with signet ring cell carcinoma: a population-based study.Eur J Med Res. 2023 Feb 2;28(1):61. doi: 10.1186/s40001-022-00970-y. Eur J Med Res. 2023. PMID: 36732873 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical